GlassScriptPhysician profile
Dennis Odie
NPI 1578593273
$12,722.86
in general payments reported to CMS, 2019-2025
49 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,583 · 2020: $1,582 · 2021: $2,132 · 2022: $1,950 · 2023: $2,192 · 2024: $1,627 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,361 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,361.13 |
| Education | $114.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,494.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,317.43 | 2019-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $965.10 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $920.70 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $763.44 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $696.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $658.17 | 2020-2025 | |
| Abbott Laboratories | $613.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $450.42 | 2022-2025 | |
| Pfizer INC. | $390.02 | 2019-2025 | |
| Amarin Pharma, INC. | $362.48 | 2019-2023 | |
| Astellas Pharma US INC | $346.74 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $322.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $321.93 | 2019-2024 | |
| Dexcom, INC. | $297.90 | 2021-2025 | Dexcom G6 Transmitter |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $285.89 | 2019-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $278.87 | 2019-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $251.64 | 2019-2025 | Gardasil, Gardasil 9, Capvaxive |
| Esperion Therapeutics, INC. | $237.81 | 2021-2025 | Nexletol |
| Horizon Therapeutics Plc | $198.74 | 2020-2023 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.33 | 2019-2025 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $143.46 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $113.37 | 2023 | Gvoke Hypopen |
| Allergan, INC. | $101.59 | 2019-2020 | |
| Exact Sciences Corporation | $86.52 | 2024-2025 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $77.83 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $71.97 | 2024-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $65.57 | 2019-2025 | Zoryve |
| Seqirus USA INC | $64.87 | 2022-2025 | Fluad, Flucelvax |
| Inspire Medical Systems, INC. | $61.23 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $55.30 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $51.02 | 2019-2022 | |
| Eisai INC. | $42.33 | 2021 | |
| Idorsia Pharmaceuticals US INC | $39.59 | 2022-2023 | Quviviq |
| Indivior INC. | $39.38 | 2024 | Sublocade |
| Corcept Therapeutics | $38.86 | 2023-2024 | Korlym |
| Sanofi Pasteur INC. | $38.31 | 2019-2023 | |
| Watermark Medical, INC. | $29.68 | 2024 | |
| Lundbeck LLC | $26.56 | 2025 | Rexulti |
| Intuity Medical INC | $23.99 | 2022 | |
| Nevro Corp. | $23.57 | 2022 | |
| Optinose US, INC. | $23.50 | 2024 | |
| Sunovion Pharmaceuticals INC. | $23.40 | 2022 | |
| Phathom Pharmaceuticals, INC. | $22.87 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $21.65 | 2023 | Evkeeza |
| Orexo US, INC. | $21.32 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.08 | 2019 | |
| Medtronic, INC. | $15.30 | 2025 | Minimed 780g |
| Phadia US INC. | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Odie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.